EurekaBio develops the EuLV™ system for the production of high-titer lentiviral vectors, addressing the challenges of cost and efficiency in cell and gene therapy manufacturing. Their CellSep™ PRO and CellSep™ MAX solutions streamline the preparation and production of cell therapy products, enhancing operational efficiency in the CGT industry.
Funding
$41.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cell and gene therapy (CGT) manufacturing faces challenges related to the high cost and inefficiency of lentiviral vector production, a critical component for gene delivery. Traditional methods often struggle to achieve the high viral titers necessary for effective therapeutic outcomes, leading to increased production costs and scalability issues. Cell therapy manufacturing also requires efficient cell separation and processing techniques to ensure product quality and reduce operational bottlenecks.
Solution
EurekaBio offers solutions designed to overcome these challenges by streamlining lentiviral vector production and cell therapy manufacturing. The EuLV™ system enables the production of high-titer lentiviral vectors, reducing costs and improving efficiency in gene delivery. The CellSep™ PRO and CellSep™ MAX solutions automate and optimize cell separation and processing, enhancing operational efficiency and product quality in cell therapy manufacturing. These integrated solutions aim to accelerate the development and commercialization of CGT products by addressing key manufacturing bottlenecks.
Target Audience
EurekaBio's primary customers include cell and gene therapy companies, research institutions, and biopharmaceutical manufacturers involved in the development and production of lentiviral vectors and cell-based therapies.
Features
- **EuLV™ System:** Enables high-titer lentiviral vector production for efficient gene delivery.
- **CellSep™ PRO and CellSep™ MAX:** Automated solutions for cell separation and processing in cell therapy manufacturing.
- **Integrated Platforms:** Combining automation and biotechnology for biological research and development.
- **Customizable Solutions:** Tailored to meet specific requirements in viral vector and cell therapy production.
- **Scalable Technology:** Designed to support both R&D and large-scale manufacturing of CGT products.